Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen - Concepedia

Concepedia

Publication | Closed Access

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen

48

Citations

29

References

2006

Year

Esteban Ribera, Carlos Azuaje, Rosa María López, M. Medina Díaz, María Feijoo-Cid, Leonor Pou, Manuel Crespo, Adrián Curran, I Ocaña, Albert Pahissa

Abstract

The combination of ATV and LPV/RTV provided high plasma concentrations of both PI, which seemed to be appropriate for patients with multiple prior therapeutic failures, yielding good tolerability and substantial antiviral efficacy.

References

	Year	Citations
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia Adriano Lazzarin, Bonaventura Clotet, David A. Cooper, New England Journal of Medicine	2003	651
Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV Kathleen Squires, Adriano Lazzarin, Jos M. Gatell, JAIDS Journal of Acquired Immune Deficiency Syndromes	2004	299
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures Margaret Johnson, Beatriz Grinsztejn, Claudia Rodríguez, AIDS	2005	249
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results Robert L. Murphy, Scott Brun, Charles B. Hicks, AIDS	2001	238
Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects Ian Sanne, Peter J. Piliero, Kathleen Squires, JAIDS Journal of Acquired Immune Deficiency Syndromes	2003	223
Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients Anne‐Marie Taburet, Christophe Piketty, Corine Chazallon, Antimicrobial Agents and Chemotherapy Antiviral CompoundHuman RetrovirusImmunologyPharmacologyResistance Mutation (Virology)	2004	211
ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO Elke S. Perloff, Su Duan, Paul R. Skolnik, Drug Metabolism and Disposition	2005	133
Assessing the Reliability of Two Toxicity Scales: Implications for Interpreting Toxicity Data Michael Brundage, Joseph L. Pater, Benny Zee JNCI Journal of the National Cancer Institute	1993	117
Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial David W. Haas, Carlos Zala, Shannon Schrader, AIDS	2003	95
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial C Cohen, Leopoldo Nieto‐Cisneros, Carlos Zala, Current Medical Research and Opinion	2005	93

Page 1